Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQuadrise Regulatory News (QED)

Share Price Information for Quadrise (QED)

Share Price is delayed by 15 minutes
Get Live Data
1.995    -0.215 (-9.73%)
Bid:
1.905
Ask:
2.19
Spread: 0.285 (14.961%)
Market Cap: £40.02m
QED Live PriceLast checked at - London Stock Exchange

Intraday Quadrise Share Chart

Q3 Trading Update

13 Feb 2015 07:00

RNS Number : 8077E
Quintain Estates & Development PLC
13 February 2015
Β 

ο»Ώ

13 February 2015

Β 

Quintain Estates & Development PLC

("Quintain" / "Company" / "Group")

Β 

Q3 Trading Update

Β 

Quintain issues the following update for the period from 26 November 2014 to 12 February 2015.

Highlights

Β· 80% of the 284 private apartments within Emerald Gardens now pre-sold

Β· Planning permission granted this week for next residential development of 370 apartments

Β· Performance of Wembley Park investment assets continues to improve

Β· New finance director, Simon Carter, to start on 26 May 2015

Maxwell James, Chief Executive of Quintain, said:

"80% of the 284 private apartments within Emerald Gardens have now been sold, a year ahead of completion, and pricing and volumes remain above initial expectations. This week's planning approval for the next residential development, Alto, will enable us to increase the number of homes under construction this year to 845, ensuring a pipeline of completions to the end of 2017 at a price point where a significant imbalance persists between supply and demand and buyers may also benefit from the Government's Help to Buy scheme."

Alto, now held as a trading asset, will comprise 370 apartments. It will be located between a new two-acre square and Emerald Gardens, the 475-home development which is due for occupation from next Spring.

The leisure quarter at the heart of Wembley Park continues to prove a strong draw for visitors and residential purchasers, with half a million people visiting London Designer Outlet in the four weeks leading up to Christmas.

Enquiries

Quintain

Maxwell James, Chief Executive

Richard Stearn, Finance Director

Β 

Tel: +44 (0)20 3219 2200

comms@quintain.co.uk

Finsbury

Jenny Davey

Charlotte Whitley

Β 

Tel: +44 (0)20 7251 3801

Quintain@rlmfinsbury.com

Β 

Forward looking statements

ThisΒ announcement is for information purposes only andΒ contains certain forward-looking statements which, by their nature, involve risk and uncertainty because they relate toΒ or depend upon future events and circumstances.

There are a number of factors which could cause actual results and developments to differ materially from those expressed or implied by these forward looking statements, including a number of factors outsideΒ Quintain's control. All forward-looking statements are based upon information known toΒ Quintain on the date of thisΒ announcement and no representation or warranty is given in relation to them, including as to their completenessΒ orΒ accuracy or the basis on which they were prepared.Β Quintain gives no undertaking to update forward-looking statements whether as a result of new information, future events or otherwise. Information contained in thisΒ announcementΒ relating to the Company should not be relied upon as an indicator of future performance.

Β 

Β 

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
TSTSFIFWEFISEIE
Date   Source Headline
15th Apr 20267:00 amRNSDirectorate change
23rd Mar 20267:00 amRNSInterim Results & Notice of Investor Presentation
19th Mar 20267:00 amRNSAppointment of Non-Executive Director
3rd Feb 20267:00 amRNS-RPublication of 2025 Sustainability Report
12th Jan 20267:00 amRNSExtension of Exclusive Agreement with Nouryon
9th Jan 20267:00 amRNSDirector/PDMR Shareholding and Directorate Change
4th Dec 202512:17 pmRNSDirector/PDMR Shareholding
28th Nov 20252:55 pmRNSResult of AGM
28th Nov 20257:00 amRNSAGM Statement
7th Nov 20253:01 pmRNSDirector/PDMR Shareholding
6th Nov 20251:46 pmRNSDirector/PDMR Shareholding
28th Oct 20255:23 pmRNSPosting of Annual Report and Notice of AGM
27th Oct 20257:00 amRNSIssue of Options and Director Dealing
13th Oct 20257:00 amRNSIssue of Share Options and Director/PDMR Dealing
29th Sep 20257:00 amRNSFinal Results and Notice of AGM
26th Sep 20257:00 amRNSValkor update
17th Sep 20257:00 amRNSSuccessful Sparkle Power Programme Testing
15th Sep 20257:00 amRNSCEO Appointment
18th Aug 20257:00 amRNSBusiness Update
25th Jul 20257:00 amRNSDirector / PDMR Shareholding
14th Jul 20258:00 amRNSDirector/PDMR Shareholding
4th Jul 202511:50 amRNSExercise of Options and Total Voting Rights
17th Jun 20257:00 amRNSJoint Development Agreement with Alder Energy LLC
10th Jun 20257:00 amRNSBusiness Update
23rd May 20257:00 amRNSExercise of Warrants
1st May 20257:01 amRNSTotal Voting Rights
1st May 20257:00 amRNSManagement Update
3rd Apr 20257:00 amRNSExercise of Share Options
1st Apr 20257:00 amRNSMAC2 Services Agreement
26th Mar 202512:46 pmRNSDirector/PDMR Shareholding
26th Mar 20257:00 amRNSLicella Joint Development Agreement
24th Mar 20257:00 amRNSInterim Results and Investor Presentation
13th Mar 20257:00 amRNS-RAppointment of Head of Marine
31st Jan 20257:00 amRNSResult of Retail Offer
30th Jan 20252:36 pmRNSIncrease of Retail Offer
28th Jan 20257:00 amRNSAppointment of Director
24th Jan 202510:04 amRNSRetail Offer - Notice of IMC Presentation
24th Jan 20257:05 amRNSRetail Offer
24th Jan 20257:00 amRNSResult of Placing and Subscription
23rd Jan 20254:51 pmRNSProposed Placing, Subscription and Retail Offer
15th Jan 20257:00 amRNSValkor License Revenues
16th Dec 20247:00 amRNSMaterial Transfer Agreement with Sparkle Power SA
5th Dec 20247:00 amRNS-RbioMSAR™ Development Update
26th Nov 20247:00 amRNSProject Agreement with MSC and Cargill
25th Nov 20247:00 amRNSCollaboration Agreement with Auramarine
22nd Nov 20244:57 pmRNSResult of AGM
22nd Nov 20247:00 amRNSAGM Statement
25th Oct 20244:05 pmRNSPosting of Annual Report & Notice of AGM
30th Sep 20247:00 amRNSFinal Results and Notice of AGM
2nd Aug 20247:00 amRNSIssue of Share Options and Director/PDMR Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.